Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.
Last trade$1.23
Day change+$0.09 (+7.89%)
Day range$0.983 – $1.28
Volume1,015,827
Market cap$10M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$9.94M
Price / earnings
—
Price / book
3.03×
Price / sales
730.7×
EV / sales
1,434.9×
EV / EBITDA
-2.17×
Profitability
Earnings per share
-$1.66
Return on assets
-73.89%
Return on equity
-440.15%
Dividend yield
0%
Liquidity and leverage
Debt / equity
3.35×
Current ratio
0.13×
Quick ratio
0.12×
Cash ratio
0.09×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$4.49M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AIMD, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$152
$161
$11.12K
$2.17K
$4.66K
$106.21K
$0
$0
Cost of revenue
$53
$763
$1.6K
$477
$937
$18.23K
-$79
$547
Gross profit
$99
-$602
$9.52K
$1.69K
$3.73K
$87.97K
$79
-$547
Selling, general and administrative
$2.55M
$593.19K
$2.18M
$795.25K
$1.84M
$1.53M
$2.31M
$1.02M
Research and development
$1.85M
$1.69M
$2.12M
$1.99M
$1.91M
$1.72M
$2.33M
$2.02M
Total operating expenses
$4.4M
$2.28M
$4.31M
$2.79M
$3.75M
$3.25M
$4.63M
$3.04M
Operating income
-$4.4M
-$2.28M
-$4.3M
-$2.78M
-$3.75M
-$3.16M
-$4.63M
-$3.04M
Interest expense
-$200.16K
-$176.88K
-$176.92K
-$176.58K
-$177.96K
-$180.45K
-$184.37K
-$264.64K
Income before taxes
-$4.59M
-$2.46M
-$4.47M
-$2.93M
-$4.08M
-$3.29M
-$4.65M
-$3.7M
Income taxes
$0
$0
$800
$0
$0
$0
$800
$0
Net income
-$4.59M
-$2.46M
-$4.47M
-$2.93M
-$4.08M
-$3.29M
-$4.65M
-$3.7M
Net income attributable to common shareholders
-$4.59M
-$2.46M
-$4.47M
-$2.93M
-$4.08M
-$3.29M
-$4.65M
-$3.7M
EBITDA
-$3.21M
-$1.11M
-$3.1M
-$1.58M
-$2.55M
-$1.99M
-$3.44M
-$1.83M
Basic earnings per share
-$0.62
-$0.41
-$0.85
-$0.64
-$0.99
-$1.04
-$1.61
-$1.64
Diluted earnings per share
-$0.62
-$0.41
-$0.85
-$0.64
-$0.99
-$1.04
-$1.61
-$1.64
Recent news
Company coverage with links to the original publishers.
Biotechnology company Ainos reported its Q2 2025 financial results, marking its first commercial revenue through AI Nose platform partnerships and ongoing VELDONA therapy clinical trials, while experiencing increased operating expenses and cash decline.
Ainos Inc., a pharmaceutical company, has received a notice from Nasdaq indicating that its stock price has been below the minimum required bid price for continued listing. The company has been granted a period of 180 days to regain compliance, but if it fails to do so, it may face delisting procedures.
Here's what types of data you should use to buy and sell penny stocks
The post What Data Should You Use to Trade Penny Stocks? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Here's how elections impact penny stocks in 2024
The post How Elections Impact Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance.
Marvell said fourth-quarter revenue increased 1% year-over-year to $1.427 billion, which beat the consensus estimate of $1.42 billion. The chip designer reported quarterly earnings of 46 cents per share, which was in line with analyst estimates.
Marvell sees first-quarter revenue of $1.15 billion, plus or minus 5%, versus estimates of $1.371 billion. The company sees first-quarter adjusted earnings of 23 cents per share, plus or minus 5 cents per share, versus estimates of 40 cents per share. The company authorized a $3 billion buyback.
Marvell Technology shares dipped 9.6% to $76.91 on Friday.
Here are some other stocks moving in today's mid-day session.
Gainers
Ainos, Inc. (NASDAQ: AIMD) jumped 140% to $2.6899 after dipping 18% on Thursday.
Psyence Biomedical Ltd. (NASDAQ: PBM) shares climbed 139% to $3.0350. Psyence Biomedical recently announced its subsidiary, Psyence Australia, received Human Research Ethics Committee approval to initiate its Phase IIb study.
Safe and Green Development Corporation (NASDAQ: SGD) shares jumped 138% to $1.57 after the company announced financing for the Norman Berry Expansion in Atlanta, Georgia.
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) shares climbed 48.5% to $1.36. MIRA Pharmaceuticals, last month, announced a research collaboration with Pharmaseed to research and evaluate Ketamir for patients with major depressive disorder and post-traumatic stress disorder.
CERo Therapeutics Holdings, Inc. (NASDAQ: CERO) shares climbed 35.4% to $4.17 after surging over 20% on Thursday. CERo Therapeutics recently announced the publication of preclinical research analyzing CER-1236 in targeting Acute Myelogenous Leukemia tumor cells from human patients.
Willdan Group, Inc. (NASDAQ: WLDN) gained 30.4% to $25.89 after the company reported better-than-expected fourth-quarter financial results and issued FY24 guidance above estimates. Also, the company secured a contract worth approximately $30 million to $50 million over three years.
The Joint Corp. (NASDAQ: JYNT) gained 29% to $11.80 following fourth-quarter results.
Smith & Wesson Brands, Inc. (NASDAQ: SWBI) jumped 25.8% to $16.91 after the company reported better-than-expected third-quarter financial results.
Research Frontiers Incorporated ...
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.